E-grāmata: Cancer Detection and Diagnosis: A Handbook of Emerging Technologies [Taylor & Francis e-book]

Near-infrared macroscopic and mesoscopic fluorescence lifetime FRET
imaging to measure intra-tumor heterogeneity of antibody-target engagement.
Combined Reflectance Confocal Microscopy- Optical Coherence Tomography for
Skin Cancer Detection and Therapy GuidanceIn Vivo Confocal Laser
Endomicroscopy: An Imaging Biomarker for Risk Stratification of Precancerous
Pancreatic Cystic Lesions. Portable confocal microscopy for aiding diagnosis
and treatment of skin cancer
Quantitative fluorescence imaging, light-triggering and monitoring of
chemodrug release from liposomes in vivo by a mesoscopic-scale theranostic
endoscope.Fluorescence Imitating Brightfield Imaging (FIBI): A simple
slide-free microscopy approach.Fluorescently-labeled tyrosine kinase
inhibitors for intracellular protein target imaging.Real-time Cancer
Metabolism Detection Using a Nanocoil Integrated Hyperpolarized Micromagnetic
Resonance Spectrometer. Detection of TMEM doorways and their activity
required for metastasis. Reading the Reader: Utilizing Eye-Movements and
Machine Learning to Enhance Accuracy. During Diagnostic Visual Search.Optical
Imaging Technology for In Vivo Tumor Detection.Adapting Image Foundational
Model to Identify Tumor Budding from H&E Images in Colorectal Cancer
Diagnostics.Quantitative Phase Imaging for Assessing Tumor Cell
Adaptability.An Exo-PROS Biosensor Simultaneously Detects Tumor-Derived
Exosomal Protein-MicroRNA Pairs for Lung and Breast Cancer
Diagnosis.Epigenetic Tools for Guiding Low Dose Computerized Tomography
(LDCT) Screening Decision Making.Multi-View Models for Colorectal Polyps
Detection in CT Colonography.Hybrid Multi-dimensional MRI of Prostate
Cancer.Detection and Characterization of Brain Metastases Using Quantitative
Chemical Exchange Saturation Transfer MRFingerprinting (CEST-MRF).Narrow-Beam
CT: A Solution to the Limitations in Breast Cancer Screening.Broadband
Coherent Anti-Stokes Raman Scattering Microscopy for Metabolic and Phenotypic
Imaging in Cancer.
Spatial multiplexed immunofluorescence imaging in exploring tumor immune
microenvironment of melanoma.
Spectroscopic Optical Coherence Tomography for in situ analysis of colonic
epithelium.Analysis of Circulating Tumor DNA (ctDNA) by Digital Droplet PCR
(ddPCR).Non-invasively monitoring the delivery of DNA alkylating agents and
cellular responses to these agents using chemical exchange saturation
transfer magnetic resonance imaging.Clonal Analysis of Cancer by
Mitochondrial DNA Barcoding.Implementing Clinical Risk Assessment for Genetic
Susceptibility to Cancer: Challenges and Successes in a Statewide
Initiative.Assessing tumor tissue for the alternative lengthening of
telomeres (ALT) phenotype.Click Chemistry-Mediated Enrichment of
Tumor-Derived Extracellular Vesicles for RNA-Based Digital
Scoring.Identifying Methods to Deliver Mutant p53-basedDiagnostics and
Therapeutics to Target the Previously Undruggable.DNA methylation biomarkers
for preoperative diagnostic of thyroid nodules.
Utilizing RADAR for the Integration of Genomic Data and Immunotherapy Targets
in Precision Oncology for Multiple Myeloma.Nanopore Whole Transcriptome
Sequencing Offers the Potential for Accessible Classification of Pediatric
Cancers.Quantitative detection of cancer nucleic acid biomarkers with a
selective solid-state nanopore assay.Isolation and characterization of
cell-free RNA from liquid biopsy taken from cancer patients.The Use of
Dielectrophoresis to Recover Cancer. Derived Nanoparticles Straight from
Undiluted Human Plasma for Cancer. Detection Applications.Conditional
Reprogramming: A. Living Biomarker and Phenotypic Screening Drug Platform for
Urological Cancer.Proteolytic Activity Signatures As Candidate. Biomarkers
for Thyroid Cancer. Carbohydrate microarrays identify the stage-specific
embryonic antigen (SSEA)-0 as a novel oncofetal cancer marker.Collective
Attributes of Extracellular Vesicles as Biomarkers for Cancer Detection
.Using a gamified mobile app approach to train tobacco control program
implementers in schools in India. Parallel Reaction Monitoring (PRM)
Quantitative. Analysis of Glycopeptide Biomarkers from Patient
Serum.Point-of-care technologies for molecular subtyping of breast cancer in
low- and middle-income countries.Development Of LLM For Prostate Cancer - The
Need for Domain-Tailored Training.Biosample and Method Selection for Marker
Studies.Subharmonic-aided pressure estimation for evaluating cancer.
Development and Implementation of a Method for Registering Prostate-specific
Antigen (PSA) Biosensor-based Assay Results in a Personalized QR Code. Deep
Learning-based Colon Segmentation for Accurate Colorectal Polyps Detection.
Emerging Blood-based Tests for Colorectal Cancer Screening: Advances,
Challenges and Future Directions. Microfluidic Isolation and Molecular
Characterization of Circulating Tumor Cells in Prostate Cancer. Chemical
Imaging for Next-generation Histopathology. GALAD Score and Extracellular
Vesicle-based Assays for Early Detection of Hepatocellular Carcinoma. Using
epidemiologic research methods to adapt a human papillomavirus assay for
cervical cancer screening in low and middle income countries. Organoid Models
for Early Detection and Diagnosis of Colorectal Cancer. Experimental Methods
for Establishing and Maintaining Canine Bladder Cancer Organoids. Top-down
Proteomics of Cancer Cells by Advanced Capillary Electrophoresis-Mass
Spectrometry.

Miguel Ossandon has a dual background in clinical laboratory and computer science. He started working in cancer research at the Lombardi Cancer Center at Georgetown University where he also began his undergraduate training in computer science. He has been working for the National Cancer Institute since 2007. Miguel received his masters degree at the George Washington University and PhD in computer science at the University of Maryland Baltimore County. As a program director in the Diagnostic Biomarkers and Technology Branch, he manages a grant portfolio related to computational modeling and machine learning approaches for cancer diagnosis, digital image processing/analysis, and microfluidic and circulating tumor cell technology.

Ben Prickril is a former US government official working at the US National Institutes of Health, National Cancer Institute. He has a background in medically related chemistry, microbiology, immunology, patenting and intellectual property, and global health. International research development includes experience in France, Turkey, Ukraine, Czech Republic and Burkina Faso. He received his PhD from the University of Georgia.

Avraham Rasooly is in the Division of Cancer Treatment and Diagnosis, National Cancer Institute. He has been responsible for developing research programs on new approaches for cancer therapy, including technologies for microbial-based cancer therapy. He received his PhD from Michigan State University.